Combination treatment with PARP inhibitors (e.g., olaparib or niraparib) and anti-PD-L1 therapy has demonstrated superior tumor regression in BRCA1/2-mutant models compared with either monotherapy [98,99]. Here, PARP1 is linked to neoplasm.